|
1
|
Hemminki A, Markie D, Tomlinson I,
Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M,
Höglund P, et al: A serine/threonine kinase gene defective in
Peutz-Jeghers syndrome. Nature. 391:184–187. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hearle N, Schumacher V, Menko FH,
Olschwang S, Boardman LA, Gille JJ, Keller JJ, Westerman AM, Scott
RJ, Lim W, et al: Frequency and spectrum of cancers in the
Peutz–Jeghers syndrome. Clin Cancer Res. 12:3209–3215. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanchez-Cespedes M, Parrella P, Esteller
M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG and Sidransky
D: Inactivation of LKB1/STK11 is a common event in adenocarcinomas
of the lung. Cancer Res. 62:3659–3662. 2002.PubMed/NCBI
|
|
4
|
Matsumoto S, Iwakawa R, Takahashi K, Kohno
T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto M, Shimizu E, Minna
JD and Yokota J: Prevalence and specificity of LKB1 genetic
alteration in lung cancer. Oncogene. 26:5911–5918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhong D, Guo L, de Aguirre I, Liu X, Lamb
N, Sun SY, Gal AA, Vertino PM and Zhou W: LKB1 mutation in large
cell carcinoma of the lung. Lung Cancer. 53:285–294. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao Y, Ge G and Ji H: LKB1 in lung
cancerigenesis: A serine/threonine kinase as tumor suppressor.
Protein Cell. 2:99–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alessi DR, Sakamoto K and Bayascas JR:
LKB1-dependent signaling pathways. Annu Rev Biochem. 75:137–163.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong LX, Sun LL, Zhang X, Pan L, Lian LJ,
Chen Z and Zhong DS: Negative regulation of mTOR activity by
LKB1-AMPK signaling in non-small cell lung cancer cells. Acta
Pharmacol Sin. 34:314–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Woods A, Johnstone SR, Dickerson K, Leiper
FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M and
Carling D: LKB1 is the upstream kinase in the AMP-activated protein
kinase cascade. Curr Biol. 13:2004–2008. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tiainen M, Ylikorkala A and Makela TP:
Growth suppression by LKB1 is mediated by a G1 cell cycle arrest.
Proc Natl Acad Sci USA. 96:9248–9251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tiainen M, Vaahtomeri K, Ylikorkala A and
Makela TP: Growth arrest by the LKB1 tumor suppressor: Induction of
p21(WAF1/CIP1). Hum Mol Genet. 11:1497–1504. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng PY and Berger SL: LKB1 is recruited
to the p21/WAF1 promoter by p53 to mediate transcriptional
activation. Cancer Res. 66:10701–10708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhong DS, Sun LL and Dong LX: Molecular
mechanisms of LKB1 induced cell cycle arrest. Thorac Cancer.
4:229–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
el-Deiry WS, Tokino T, Velculescu VE, Levy
DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and
Vogelstein B: WAF1, a potential mediator of p53 tumor suppression.
Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun LL, Zhong DS, Wu S, Bai H and Chen Z:
Establishment and gene expression profiling of LKB1 stable
knockdown lung cancer cell line. Chin Med J (Engl). 124:2028–2032.
2011.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu H, Zhou Y, Coughlan KA, Ding Y, Wang S,
Wu Y, Song P and Zou MH: AMPKα1 deficiency promotes cellular
proliferation and DNA damage via p21/WAF1 reduction in mouse
embryonic fibroblasts. Biochim Biophys Acta. 1853:65–73. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shieh SY, Ikeda M, Taya Y and Prives C:
DNA damage-induced phosphorylation of p53 alleviates inhibition by
MDM2. Cell. 91:325–334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hardie DG and Alessi DR: LKB1 and AMPK and
the cancer-metabolism link-ten years after. BMC Biol. 11:362013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Setogawa T, Shinozaki-Yabana S, Masuda T,
Matsuura K and Akiyama T: The tumor suppressor LKB1 induces p21
expression in collaboration with LMO4, GATA-6, and Ldb1. Biochem
Biophys Res Commun. 343:1186–1190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Imamura K1, Ogura T, Kishimoto A,
Kaminishi M and Esumi H: Cell cycle regulation via p53
phosphorylation by a 5′-AMP activated protein kinase activator,
5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human
hepatocellular carcinoma cell line. Biochem Biophys Res Commun.
287:562–567. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jones RG, Plas DR, Kubek S, Buzzai M, Mu
J, Xu Y, Birnbaum MJ and Thompson CB: AMP-activated protein kinase
induces a p53-dependent metabolic checkpoint. Mol Cell. 18:283–293.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Igata M, Motoshima H, Tsuruzoe K, Kojima
K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Kukidome D,
et al: Adenosine monophosphate-activated protein kinase suppresses
vascular smooth muscle cell proliferation through the inhibition of
cell cycle progression. Circ Res. 97:837–844. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun B, Ross SM, Rowley S, Adeleye Y and
Clewell RA: Contribution of ATM and ATR kinase pathways to
p53mediated response in etoposide and methyl methanesulfonate
induced DNA damage. Environ Mol Mutagen. 58:72–83. 2017. View Article : Google Scholar : PubMed/NCBI
|
